A randomized phase IIb Trial of Pulmicort Turbuhaler (Budesonide) in people with dysplasia of the bronchial epithelium

Clinical Cancer Research

Volumn 10, Issue 19, 2004, Pages 6502-6511

  Lam, Stephen ^a,f   LeRiche, Jean C ^a   McWilliams, Annette ^a   MacAulay, Calum ^a   Dyachkova, Yulia ^a   Szabo, Eva ^b   Mayo, John ^c   Schellenberg, Robert ^d   Coldmam, Andy ^a   Hawk, Ernest ^b   Gazdar, Adi ^e  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b NATIONAL CANCER INSTITUTE   (United States)

^c VANCOUVER GENERAL HOSPITAL   (Canada)

^d ST PAUL S HOSPITAL   (Canada)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; KI 67 ANTIGEN; PLACEBO; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ARTICLE; AUTOFLUORESCENCE; BRONCHOSCOPY; BRONCHUS BIOPSY; BRONCHUS MUCOSA; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG SAFETY; DRY EYE; EPITHELIUM DYSPLASIA; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HISTOPATHOLOGY; HOARSENESS; HUMAN; HUMAN TISSUE; LARYNX DISORDER; LUNG CANCER; LUNG NODULE; MAJOR CLINICAL STUDY; MALE; MOUTH DISEASE; NAUSEA; OCULAR PRURITUS; PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN BRUISING; SMOKING; STATISTICAL SIGNIFICANCE; TASTE DISORDER; THIRST; THROAT DISEASE; THRUSH; VISUAL IMPAIRMENT; XEROSTOMIA;

ADMINISTRATION, INHALATION; ADULT; AGED; BIOPSY; BRONCHI; BRONCHODILATOR AGENTS; BUDESONIDE; COUGH; DOUBLE-BLIND METHOD; FATIGUE; FEMALE; HEADACHE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LOGISTIC MODELS; MALE; MIDDLE AGED; PHARYNX; PRECANCEROUS CONDITIONS; PROTO-ONCOGENE PROTEINS C-BCL-2; RESPIRATORY MUCOSA; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 5144228550     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0686     Document Type: Article

References (43)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004, CA - Cancer J Clin 2004;54:8-29.
2. Halpern MT, Gillespie BW, Warner KE. Patterns of absolute risk of lung cancer mortality in former smokers. J Natl Cancer Inst (Bethesda) 1993;85:457-64.
3. Tong L, Spitz MR, Fueger JJ, Amos CA. Lung cancer in former smokers. Cancer (Phila.) 1996;78:1004-10.
4. Sporn MB, Newton DL. Chemoprevention of cancer with retinoids. Fed Proc 1979;38:2528-34.
5. Hong WK, Sporn MB. Recent advances in chemoprevention of cancer. Science (Wash. DC) 1997;278:1073-7.
6. McWilliams A, Lam S. New approaches to lung cancer prevention. Curr Oncol Rep 2002;4:467-94.
7. Greenberg AK, Hu J, Basu S, et al. Glucocorticoids inhibit lung cancer cell growth through both the extracellular signal-related kinase pathways and cell cycle regulators. Am J Respir Cell Mol Biol 2002; 27:320-8.
8. Wattenberg LW, Wiedmann TS, Estensen RD, Zimmerman CL, Steele VE, Kelloff GJ. Chemoprevention of pulmonary carcinogenesis by aerosolized budesonide in female A/J mice. Cancer Res 1997;57:5489-92.
9. Wattenberg LW, Estensen RD. Studies of chemopreventive effects of budesonide on benzo[a]pyrene-induced neoplasia of the lung of female A/J mice. Carcinogenesis (Lond.) 1997;18:2015-7.
10. Wattenberg LW, Wiedmann TS, Estensen RD, et al. Chemoprevention of pulmonary carcinogenesis by brief exposures to aerosolized budesonide or beclomethasone dipropionate and by the combination of aerosolized budesonide and dietary myo-inositol. Carcinogenesis (Lond.) 2000;21:179-82.
11. Pereira MA, Gunning WT, Kramer PM, et al. Prevention of mouse lung tumors by budesonide and its modulation of biomarkers. Carcinogenesis (Lond.) 2002;23:1185-92.
12. Lam S, MacAulay C, leRiche JC, Gazdar AF. Key issues in lung cancer chemoprevention trials of new agents. In: Senn H-J, Morant R, editors. Recent results in cancer research: tumor prevention and genetics, Vol. 163. Berlin: Springer Verlag; 2003. p. 182-95.
13. Payne PW, Sebo TJ, Doudkine A, et al. Sputum screening by quantitative microscopy: a reexamination of a portion of the National Cancer Institute Cooperative Early Lung Cancer Study. Mayo Clin Proc 1997;72:697-704.
14. Garner DM, Harrison A, MacAulay C, Palcic B. Cyto-Savant and its use in automated screening of cervical smears. In: Wied GL, Bartels PH, Rosenthal PH, Schenck U, editors. Compendium on the computerized cytology and histology laboratory. Chicago: Tutorials of Cytology; 1994. p. 346-52.
15. Lam S, Kennedy T, Unger M, et al. Localization of bronchial intraepithelial neoplastic lesions by fluorescence bronchoscopy. Chest 1998;113:696-702.
16. Lam S, leRiche JC, Zheng Y, et al. Sex-related differences in bronchial epithelial changes associated with tobacco smoking. J Natl Cancer Inst (Bethesda) 1999;91:691-6.
17. Lam S, leRiche JC, Kijek K, Phillips D. Effect of bronchial lavage volume on cellular and protein recovery. Chest 1985;88:856-9.
18. Lam S, Chan H, leRiche JC, Chan-Yeung M, Salari H. Release of leukotrienes in patients with bronchial asthma. J Allergy Clin Immunol 1988;81:711-7.
19. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E. Histologic and graphical text slides for the histological typing of lung and pleural tumors. In: World Health Organization pathology panel: World Health Organization. International histological classification of tumors, 3rd ed. Berlin: Springer Verlag; 1999. p 5.
20. Salari H, Schellenberg RR. Stimulation of human airway epithelial cells by platelet activating factor (PAF) and arachidonic acid produces 15-hydroxyeicosatetraenoic acid (15-HETE) capable of contracting bronchial smooth muscle. Pulm Pharmacol 1991;4:1-7.
21. Shi SR, Key ME, Kalra KL. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 1991;39:741-8.
22. Shi SR, Cote RJ, Yang C, et al. Development of an optimal protocol for antigen retrieval: a 'test battery' approach exemplified with reference to the staining of retinoblastoma protein (pRB) in formalin-fixed paraffin sections. J Pathol 1996;179:347-52.
23. McWilliams A, Mayo J, MacDonald S, et al. Lung cancer screening: a different paradigm. Am J Respir Crit Care Med 2003;168:1167-73.
24. Lam S, Xu X, Parker-Klein H, et al. Surrogate end-point biomarker analysis in a retinol chemoprevention trial in current and former smokers with bronchial dysplasia. Int J Oncol 2003;23:1607-13.
25. Bach PB, Kattan MW, Thornquist MD, et al. Variations in lung cancer risk among smokers. J Natl Cancer Inst (Bethesda) 2003;95(6):470-8.
26. Lam S, MacAulay C, leRiche JC, et al. A randomized phase IIb trial of anethole dithiolethione in smokers with bronchial dysplasia. J Natl Cancer Inst (Bethesda) 2002;94:1001-9.
27. Peto R, Darby S, Deo H, Silcocko P, Whitley E, Doll R. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. Br Med J 2000;321:323-9.
28. Wistuba II, Mao L, Gazdar AF. Smoking molecular damage in bronchial epithelium. Oncogene 2002;21:7298-306.
29. Wistuba II, Behrens C, Virmani AK, et al. Allelic losses at chromosome 8p21-23 are early and frequent events at the pathogenesis of lung cancer. Cancer Res 1999;59:1973-9.
30. Wistuba II, Behrens C, Virmani AK, et al. High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res 2000; 60:1949-60.
31. Wang Y, Zhang Z, Kastens E, Lubet RA, You M. Mice with alterations in both p53 and Ink4a/Arf display a striking increase in lung tumor multiplicity and progression: differential chemopreventive effect of budesonide in wild-type and mutant A/J mice. Cancer Res 2003;63: 4389-95.
32. Kerr K. Adenomatous hyperplasia and the origin of peripheral adenocarcinoma of the lung. In: Corrin B, editor. Pathology of lung tumours. New York: Churchill Livingstone; 1997. p. 119-33.
33. Miller R. Bronchoalveolar cell adenomas. Am J Surg Pathol 1990;14:904-12.
34. Robles AI, Linke SP, Harris CC. The p53 network in lung carcinogenesis. Oncogene 2002;21:3898-907.
35. Martin B, Paesmans M, Berghmans FB, et al. Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2003;89:55-64.
36. Paulwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999;340:1948-53.
37. The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000;343:1902-9.
38. Culpitt SV, Nightingale JA, Barnes PJ. Effect of high dose inhaled steroid on cells, cytokines and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Resp Crit Med 1999;160:1635-9.
39. Keatings VM, Jatakanon A, Worsdell YM, Barnes PJ. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997;155:542-8.
40. Turato G, DiStefano A, Maestrelli P, et al. Effect of smoking cessation on airway inflammation in chronic bronchitis. Am J Respir Crit Care Med 1995;152:1262-7.
41. Rutgers SR, Postma DS, ten Hacken NH, et al. Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax 2000;55:12-8.
42. Barnes PJ. New concepts in chronic obstructive pulmonary disease. Annu Rev Med 2003;54:113-29.
43. Ito K, Lim S, Caramori G, Chung KF, Barnes PJ, Adcock IM. Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophages. FASEB J 2001;15:1110-2.